Grant Life Sciences Awarded Patent for Vital Components of Blood-Based Cervical Cancer Test Thursday September 22, 4:51 pm ET Patent Marks Major Company Milestone and Significant Step toward Product Commercialization
MURRAY, Utah--(BUSINESS WIRE)--Sept. 22, 2005--Grant Life Sciences (OTC Bulletin Board: GLIF - News) today announced that it was recently awarded a U. S. patent for essential components of its proprietary technology for diagnosing cervical cancer. ADVERTISEMENT
"The issuance of this patent represents a significant milestone for Grant Life Sciences in our drive toward an effective, commercial blood test for cervical cancer and its precursors," said Michael Ahlin, the company's vice president and founder. "Issuance is a validation of our original and ongoing work on cancer detection, and we can now progress more effectively and confidently toward further development and ultimate commercialization of our cervical cancer test."
The patent (Number 6,933,123) encompasses essential components of the company's proprietary technology: "Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers."
Ahlin explained that cervical cancer remains the second most common cancer among women worldwide. For over 50 years, the Pap smear has been the most widely used method for screening for cervical cancer, but it has proven consistently inadequate for detecting the disease in its early, most curable stages. As a result, each year about 500,000 women worldwide are diagnosed with invasive cervical cancer, and more than 300,000 women die of the disease.
According to Ahlin, the overwhelming cause of cervical cancer (over 99% of cases) is infection by the human papillomavirus (HPV). The newly issued patent encompasses novel amino acid sequences, or small proteins, isolated from particular genetic regions of HPV types 16 and 18, which are responsible for most cervical cancers. These novel proteins developed by Grant Life Sciences function as probes in a more rapid, sensitive, and specific test for detecting or diagnosing HPV-associated cellular abnormalities, precancerous lesions, and cancers.
"There remains an urgent need for a comparatively simple, inexpensive and sensitive blood test for the early detection of cervical cancer," Ahlin stated. "We at Grant Life Sciences are proud and excited that we have been moving progressively toward meeting that need."
Ahlin noted that Institutional Review Board-approved studies at multiple medical centers are underway in the move to perfect and finalize the cervical cancer test.
IP: Logged |
posted
Monday's Sept 26th Stock Trading Alert Cargo Connection Logistics Holding, Inc. (OTC BB: CRGO), Grant Life Sciences (OTC BB: GLIF), Empyrean Holdings, Inc. (OTC BB: EPYH), Biophan Technologies, Inc. (OTC BB: BIPH).
Grant Life Sciences (OTC BB: GLIF)
Shares of Grant Life Sciences traded on volume of over 21.5 million shares on Friday and closed 1,210.00% higher at $0.131. The company announced last week that it has recently been awarded a U. S. patent for essential components of its proprietary technology for diagnosing cervical cancer.
IP: Logged |
Market Pulse News Alert for this AM, Stocks to Watch are: China Direct Trading Corporation (OTC BB: CHDT), Apple Computer Inc. (NASDAQ: AAPL), JDS Uniphase Corp. (NASDAQ: JDSU), and Grant Life Sciences, Inc. (OTC BB: GLIF).
Stocks in the news and acting well as of late include: Apple Computer Inc. (NASDAQ: AAPL), JDS Uniphase Corp. (NASDAQ: JDSU), and Grant Life Sciences, Inc. (OTC BB: GLIF).
IP: Logged |
Topic Closed
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
